Citations

Clear

1792 citation(s) found for "Stephanie".

Longitudinal Progression of Patients with Long COVID Treated in a Post-COVID Clinic: A Cross-Sectional Survey
Yadav, Siddhant, Schroeder, Darrell R. , Croghan, Ivana T. , Mueller, Michael , Grach, Stephanie L. , Aakre, Christopher A. , Gilman, Elizabeth A. , Stephenson, Christopher R. , Overgaard, Joshua , Collins, Nerissa M. , Lawson, Donna K. , Thompson, Ann M., Natividad, Lasonya T., Hurt, Ryan T. , Croghan, Ivana T , Grach, Stephanie L , Mohamed Elfadil, Osman , Ganesh, Ravindra , Schroeder, Darrell , Thompson, Ann M., Elfadil, Osman Mohamed , Ganesh, Ravindra

Mayo Clinic

Journal of Primary Care & Community Health | May 30, 2024 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/21501319241258671 | PMID 38813984 Get It

Background: In addition to the morbidity and mortality associated with acute infection, COVID-19 has been associated with persistent symptoms (>30 days), often referred to as Long COVID (LC). LC symptoms often cluster into phenotypes, resembling conditions such as fibromyalgia, postural orthostatic tachycardiac syndrome (POTS), and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). LC clinics have been established to best address the needs of LC patients and continuity of care. We developed a cross-sectional survey to assess treatment response through our LC Clinic (LCC). Methods: A 25-question survey (1-10 Likert scale) was expert- and content-validated by LCC clinicians, patients, and patient advocates. The survey assessed LC symptoms and the helpfulness of different interventions, including medications and supplements. A total of 852 LCC patients were asked to complete the survey, with 536 (62.9%) responding. Results: The mean time from associated COVID-19 infection to survey completion was 23.2 ± 6.4 months. The mean age of responders was 52.3 ± 14.1 (63% females). Self-reported symptoms were all significantly improved ( P < .001) from the initial visit to the LCC (baseline) to the time of the follow-up survey. However, only 4.5% (24/536) of patients rated all symptoms low (1-2) at the time of the survey, indicating low levels of full recovery in our cohort. The patients rated numerous interventions as being helpful, including low-dose naltrexone (45/77; 58%), vagal nerve stimulation (18/34; 53%), and fisetin (28/44; 64%). Conclusions: Patients report general improvements in symptoms following the initial LCC visit, but complete recovery rates remain low at 23.2 ± 6.4 months.
Two genome-wide interaction loci modify the association of nonsteroidal anti-inflammatory drugs with colorectal cancer
Drew, David A. , Kim, Andre E. , Lin, Yi , Morrison, John L. , Lewinger, Juan Pablo , Fu, Yubo, Zemlianskaia, Natalia , Díez‐Obrero, Virginia , Baurley, James W. , Wu, Anna H. , Prentice, Ross L. , Harlid, Sophia , Barry, Elizabeth L. , Berndt, Sonja I. , Bouras, Emmanouil , Burnett‐Hartman, Andrea N. , Casey, Graham , Chang‐Claude, Jenny , Figueiredo, Jane C. , Gruber, Stephen B. , Gsur, Andrea , Harrison, Tabitha A. , Huyghe, Jeroen R. , Jordahl, Kristina M. , Kundaje, Anshul , Li, Li , Newton, Christina C. , Obón‐Santacana, Mireia , Pai, Rish K. , Papadimitriou, Nikos , Scacheri, Peter C. , Schmit, Stephanie L. , Thomas, Duncan C. , Duijnhoven, Fränzel J.B. van , Guelpen, Bethany Van , Peters, Ulrike , Gauderman, W. James , Morrison, John L , Lewinger, Juan Pablo , Wang, Jun , Zemlianskaia, Natalia , Bien, Stephanie A , Dimou, Niki , Buchanan, Daniel D , Potter, John D , Prentice, Ross L , Harlid, Sophia , Arndt, Volker , Bouras, Emmanouil , Carreras-Torres, Robert , Casey, Graham , Devall, Matthew A M , Gruber, Stephen B , Gsur, Andrea , Gunter, Marc J , Harrison, Tabitha A , Hoffmeister, Michael , Huyghe, Jeroen R , Jenkins, Mark A , Jordahl, Kristina M , Kundaje, Anshul , Li, Li , Lynch, Brigid M , Nassir, Rami , Newton, Christina C , Ogino, Shuji , Ose, Jennifer , Pai, R K , Palmer, Julie R , Pardamean, Bens , Pellatt, Andrew J , Peoples, Anita R , Platz, Elizabeth A. , Rennert, Gad , Ruiz-Narvaez, Edward , Sakoda, Lori C , Schmit, Stephanie L , Schoen, Robert E , Su, Yu-Ru , Tian, Yu , Tsilidis, Konstantinos K , Ulrich, Cornelia M , Um, Caroline Y , van Duijnhoven, Fränzel J B , Van Guelpen, Bethany , Hsu, Li , Moreno, Victor , Peters, Ulrike , Chan, Andrew T , Gauderman, W James , Drew, David A , Obón-Santacana, Mireia , Papadimitriou, Nikos , Diez-Obrero, Virginia , Qu, Conghui , Kawaguchi, Eric , Bien, Stephanie A. , Dimou, Niki , Albanes, Demetrius , Buchanan, Daniel D. , Potter, John D. , Arndt, Volker , Brenner, Hermann , Budiarto, Arif , Campbell, Peter T. , Carreras‐Torres, Robert , Conti, David V. , Gunter, Marc J. , Hidaka, Akihisa , Hoffmeister, Michael , Jenkins, Mark A. , Marchand, Loı̈c Le , Murphy, Neil , Nassir, Rami , Newcomb, Polly A. , Ose, Jennifer , Palmer, Julie R. , Pardamean, Bens , Pellatt, Andrew J. , Rennert, Gad , Sakoda, Lori C. , Schoen, Robert E. , Stern, Mariana Carla , Tian, Yu , Tsilidis, Konstantinos K. , Ulrich, Cornelia M. , Um, Caroline Y. , White, Emily E. , Moreno, Vı́ctor , Chan, Andrew T.

Mayo Clinic

Science Advances | May 29, 2024 | Volume: 10 | Issue: 22 | Pages: No page available

10.1126/sciadv.adk3121 | PMID 38809988 Get It

Regular, long-term aspirin use may act synergistically with genetic variants, particularly those in mechanistically relevant pathways, to confer a protective effect on colorectal cancer (CRC) risk. We leveraged pooled data from 52 clinical trial, cohort, and case-control studies that included 30,806 CRC cases and 41,861 controls of European ancestry to conduct a genome-wide interaction scan between regular aspirin/nonsteroidal anti-inflammatory drug (NSAID) use and imputed genetic variants. After adjusting for multiple comparisons, we identified statistically significant interactions between regular aspirin/NSAID use and variants in 6q24.1 (top hit rs72833769 ), which has evidence of influencing expression of TBC1D7 (a subunit of the TSC1-TSC2 complex, a key regulator of MTOR activity), and variants in 5p13.1 (top hit rs350047 ), which is associated with expression of PTGER4 (codes a cell surface receptor directly involved in the mode of action of aspirin). Genetic variants with functional impact may modulate the chemopreventive effect of regular aspirin use, and our study identifies putative previously unidentified targets for additional mechanistic interrogation.
Pro Inflammatory Cytokines Profiles of Patients With Long COVID Differ Between Variant Epochs
Ganesh, Ravindra , Yadav, Siddhant, Mueller, Michael , Aakre, Christopher A. , Gilman, Elizabeth A. , Grach, Stephanie L. , Overgaard, Joshua , Snyder, Melissa R. , Collins, Nerissa M. , Croghan, Ivana T. , Salonen, Bradley R. , Hurt, Ryan T. , Grach, Stephanie L , Croghan, Ivana T , Ganesh, Ravindra , Badley, Andrew D. , Razonable, Raymund R.

Mayo Clinic

Journal of Primary Care & Community Health | May 29, 2024 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/21501319241254751 | PMID 38808863 Get It

Background: Over 30% of patients with COVID-19 have persistent symptoms that last beyond 30 days and referred to as Long COVID. Long COVID has been associated with a persistent elevation in peripheral cytokines including interleukin-6, interleukin-1β, and tumor necrosis factor-α. This study reports cytokine profiles of patients in our clinic across SARS-COV-2 variant epochs. Methods: The clinical cytokine panel was analyzed in patients with Long COVID during periods that were stratified according to variant epoch. The 4 variant epochs were defined as: (1) wild-type through alpha, (2) alpha/beta/gamma, (3) delta, and (4) omicron variants. Results: A total of 390 patients had the clinical cytokine panel performed; the median age was 48 years (IQR 38-59) and 62% were female. Distribution by variant was wild-type and alpha, 50% (n = 196); alpha/beta/gamma, 7.9% (n = 31); delta, 18% (n = 72); and omicron, 23% (n = 91). Time to cytokine panel testing was significantly longer for the earlier epochs. Tumor necrosis factor-α ( P < .001) and interleukin 1β ( P < .001) were significantly more elevated in the earlier epochs (median of 558 days in wild-type through Alpha epoch vs 263 days in omicron epoch, P < .001)). Nucleocapsid antibodies were consistently detected across epochs. Discussion: When stratified by variant epoch, patients with early epoch Long COVID had persistently elevated peripheral pro-inflammatory cytokine levels when compared to later epoch Long COVID. Patients with Long COVID have similar clusters of symptoms across epochs, suggesting that the underlying pathology is independent of the peripheral cytokine signature.
Innervation of adipocytes is limited in mouse perivascular adipose tissue
Hanscom, Marie , Morales‐Soto, Wilmarie , Watts, Stephanie W. , Jackson, William F. , Gulbransen, Brian D.

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | May 24, 2024 | Volume: 327 | Issue: 1 | Pages: H155-H181

10.1152/ajpheart.00041.2024 | PMID 38787382 Get It

This study challenges prevailing views on neural innervation in perivascular adipose tissue (PVAT) and its role in adrenergic-driven anticontractile effects on vasculature. Contrary to existing paradigms, limited anatomical and functional connections were found between PVAT nerve fibers and adipocytes, underscoring the importance of exploring alternative mechanistic pathways. Understanding the mechanisms involved in PVAT’s anticontractile effects is critical for developing potential therapeutic interventions against dysregulated vascular tone, hypertension, and cardiovascular disease.
Overcoming challenges in real‐world evidence generation: An example from an Adult Medical Care Coordination program
Savitz, Samuel T. , Inselman, Shealeigh A., Dholakia, Ruchita, Hunt, Vicki L., Mattson, Angela, Stroebel, Robert J. , McCabe, Pamela J. , Witwer, Stephanie G. , Lampman, Michelle A. , Mattson, Angela B, Borah, Bijan J.

Mayo Clinic

Learning Health Systems | May 23, 2024 | Volume: 8 | Issue: S1 | Pages: No page available

10.1002/lrh2.10430 | PMID 39430273 Get It

AbstractThe Adult Medical Care Coordination program (“the program”) was implemented at Mayo Clinic to promote patient self‐management and improve 30‐day unplanned readmission for patients with high risk for readmission after hospital discharge. This study aimed to evaluate the impact of the program compared to usual care using a pragmatic, stepped wedge cluster randomized trial (“stepped wedge trial”). However, several challenges arose including large differences between the study arms. Our goal is to describe the challenges and present lessons learned on how to overcome such challenges and generate evidence to support practice decisions. We describe the challenges encountered during the trial, the approach to addressing these challenges, and lessons learned for other learning health system researchers facing similar challenges. The trial experienced several challenges in implementation including several clinics dropping from the study and care disruptions due to COVID‐19. Additionally, there were large differences in the patient population between the program and usual care arms. For example, the mean age was 76.8 for the program and 68.1 for usual care. Due to these differences, we adapted the methods using the propensity score matching approach that is traditionally applied to observational designs and adjusted for differences in observable characteristics. When conducting pragmatic research, researchers will encounter factors beyond their control that may introduce bias. The lessons learned include the need to weigh the tradeoffs of pragmatic design elements and the potential value of adaptive designs for pragmatic trials. Applying these lessons would promote the successful generation of evidence that informs practice decisions.
Investigating Mesenchymal Stem Cell Sources for VEGFA mRNA Transfection and In Vivo Protein Exposure
Granéli, Cecilia , Zhou, Alex X., Hong, Xuechong , Dahlqvist, Ulrika, Vaithilingam, Vijayaganapathy , Henderson, Neil , Bates, Stephanie M. , Fellows, Mick D. , Forslöw, Anna, Zhu, Xiang, Ahlström, Christine , Boianelli, Alessandro , Lerman, Lilach O. , Menzies, Robert I., Hölttä, Mikko , Hicks, Ryan , Hansen, Pernille

Mayo Clinic

Journal of the American Society of Nephrology | May 18, 2024 | Volume: 34 | Issue: 11S | Pages: 1072-1072

10.1681/asn.20233411s11072a Get It

Prognostic Model for Progression of Autosomal Dominant Polycystic Kidney Disease to Kidney Failure
Cohen, Aarón , Landsittel, Douglas , Chapman, Arlene B., Mrug, Michal , Bae, Kyongtae T., Yu, Alan S.L. , Ables, Erin , Torres, Vicente E. , Chebib, Fouad T. , Harris, Peter C. , Rahbari-Oskoui, Frederic F. , Dickinson, Stephanie , Bennett, William M. , Landsittel, Douglas P.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 34 | Issue: 11S | Pages: 209-209

10.1681/asn.20233411s1209c Get It

Clinicopathologic and Molecular Characteristics of Light Chain Crystalline Podocytopathy
Nasr, Samih H. , Said, Samar M. , Harel, Stéphanie , Osuchukwu, George A., Das, Arjun, Suchin, Elliot J., D’Agati, Vivette D. , Kudose, Satoru , Javaugue, Vincent , Das, Arjun, Suchin, Elliot J., Leung, Nelson , Bridoux, Frank

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 33 | Issue: 11S | Pages: 646-646

10.1681/asn.20223311s1646b Get It

Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial
Liu, Joyce F. , Gaillard, Stéphanie , Hendrickson, Andrea E. Wahner , Yeku, Oladapo , Jackson, Camille Gunderson, Arend, Rebecca C. , Ratner, Elena , Samnotra, Vivek, Gupta, Divya , Chung, Jon , Zhang, Hailei , Compton, Natalie, Baines, Amanda, Bacqué, Emeline , Felicetti, Brunella, Konecny, Gottfried E. , Wahner Hendrickson, Andrea E , Konecny, Gottfried E , Gaillard, Stéphanie , Yeku, Oladapo O , Diver, Elisabeth , Liu, Xiaohong

Mayo Clinic

JCO Precision Oncology | May 16, 2024 | Volume: No volume available | Issue: 8 | Pages: No page available

10.1200/po.23.00693 | PMID 38754056 Get It

PURPOSE To report the results of OPAL (ClinicalTrials.gov identifier: NCT03574779 ) cohort A, a single-arm substudy of niraparib plus dostarlimab and bevacizumab for the treatment of advanced, platinum-resistant ovarian cancer (PROC). METHODS Participants with PROC who received 1-2 previous lines of therapy were treated with niraparib (200 or 300 mg once daily), dostarlimab (500 mg once every 3 weeks for four 21-day cycles, followed by 1,000 mg once every 6 weeks), and bevacizumab (15 mg/kg once every 3 weeks). The primary end point was investigator-assessed objective response rate (ORR) per RECIST v1.1. Safety was also assessed. Exploratory biomarker end points included evaluation of changes in the tumor molecular profile and microenvironment using baseline and on-treatment tumor samples. RESULTS Of 41 enrolled participants (median age, 66.0 years [range, 37-83 years]), 9.8% had tumors that were BRCA-mutated, 19.5% were homologous recombination (HR)–deficient, and 17.1% were HR repair (HRR)–mutated. As of the cutoff date, all participants discontinued treatment. The ORR was 17.1% (80% CI, 9.8 to 27.0), including one complete response (2.4%); the disease control rate was 73.2% (80% CI, 62.3 to 82.2). Two participants withdrew before first postbaseline scan because of adverse events (AEs). Grade ≥3 treatment-emergent AEs were reported in 92.7% of participants, with the most common being hypertension (26.8%). Response was not correlated with BRCA, HRR, HR deficiency (HRD), or PD-L1 status. Changes suggesting immune activation were observed in on-treatment samples after triplet therapy. CONCLUSION Results demonstrated modest activity of niraparib, dostarlimab, and bevacizumab in participants with PROC, many of whom had prognostic factors for poor treatment response. Most participants with response were bevacizumab-naïve. No association was found with HRD, BRCA, or PD-L1 status. AEs were consistent with previous monotherapy reports, except that hypertension was reported more frequently.